COPD - Free CE Continuing Education online pharmacy, pharmacists

More documents

Recommendations

Info

Medication Class Brand Generic Availability Dosage Form FDA approval Directions Anitcholinergics- Short and long acting Atrovent ipratropium Brand only Inhaler Yes, also asthma 2 sprays (18 mcg/spray) 3—4 times per day Class Side Effects: Dry mouth, blurred vision, constipation, runny nose, irritated throat, runny nose, Spiriva tiotropium Brand only Handihaler Yes 18 mcg once per day via oral inhalation Ipitropiuim solution ipratropium Generic only Nebulizing solution Yes, also asthma 500 mcg (1 unit dose vial) 3—4 times per day via oral nebulization 1. Micromedex® Healthcare Series [intranet database]. Version 5.1. Greenwood Village, Colo: Thomson Healthcare. Available at: http://www.thomsonhc.com.ezproxy.samford.edu/ home/dispatch. Accessed March 18 2009.
AntiCholinergics & CV Risk? • Meta‐Analysis to assess CV risks associated with >30 day use of ipratropium and tiotropium vs. control in patients with <strong>COPD</strong> • 17 RCT with 7472 on anticholinergics and 7311 on control • Results: • Inhaled anticholinergics significantly increased: ▪ Risk of CV death, non‐fatal MI or stroke, RR 1.58 (95% CI, 1.21‐2.06) ▪ MI, RR 1.53, (95% CI 1.05‐2.23) ▪ CV death, RR 1.80 (95% CI 1.17‐2.77) • Stroke NOT significantly increased • Secondary outcome ‐ risk of all‐cause mortality NS difference • Need prospective RCT to accurately access CV risk
Page 1 and 2: Women Beware The Threat of COPD Cat
Page 3 and 4: Women Beware The Threat of COPD Acc
Page 5 and 6: Chronic obstructive pulmonary disea
Page 7 and 8: Clinical Presentation of COPD • S
Page 9 and 10: COPD - Defining Characteristics Spi
Page 11 and 12: Diagnosis of COPD in Women 80 70 60
Page 13 and 14: • Estimated 24 million adults wit
Page 15 and 16: • Tobacco use is the #1 cause of
Page 17 and 18: • Genetic - severe heredity defic
Page 19 and 20: Treatment Pathway
Page 22 and 23: Non Pharmacologic Therapy
Page 24 and 25: Vaccines • Flu: Annual influenza
Page 27 and 28: • Central to symptomatic manageme
Page 29: Medication Class Brand Generic Avai
Page 33 and 34: Steroids • Regular treatment does
Page 35 and 36: Brand Generic Availability Dosage F
Page 37 and 38: • Training patients to use inhale
Page 39 and 40: 66 yo woman visits PCP for a linger
Page 41 and 42: Stage II moderate COPD ‐ uncontro

COPD - Free CE Continuing Education online pharmacy, pharmacists

Create successful ePaper yourself

Delete template?

Save as template?